[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gastric-lesion\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gastric-lesion":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,52,79,110],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":33,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100581291","capsule-gastric-endoscopy-for-gastric-disease-screening-in-simulated-home-scenarios-100581291",false,"NCT06848400","Capsule Gastric Endoscopy for Gastric Disease Screening in Simulated Home Scenarios","A Multicenter, Prospective Study of Capsule Gastric Endoscopy for Gastric Disease Screening in Simulated Home Scenarios","Inclusion criteria\n\n1. Aged 18 years or older.\n2. Individuals meeting the following criteria:\n\n   i. Healthy volunteers; ii. Suspected presence of gastrointestinal diseases, with one or more of the following clinical symptoms: abdominal pain, nausea, vomiting, hematemesis, black or bloody stools, loss of appetite, bloating, or indigestion; iii. Follow-up of gastric lesions post-endoscopic resection.\n3. Willing to participate voluntarily in the clinical trial and provide written informed consent.\n4. Capable of communicating with researchers and complying with trial requirements.\n\nExclusion criteria\n\n1. Pregnant individuals.\n2. Individuals at high risk of gastrointestinal obstruction, including those identified as being at risk of gastrointestinal stenosis based on the Gastrointestinal Stenosis Assessment Form, those in whom gastrointestinal obstruction cannot be clinically excluded, or individuals with a history of gastrointestinal surgery, severe motor dysfunction, or pseudobulbar palsy.\n3. Individuals with swallowing dysfunction.\n4. Individuals deemed unfit for surgery or unwilling to undergo any surgical procedures.\n5. Participants who are unable to comprehend and\u002For comply with physician instructions during the examination.\n6. Individuals with other medical risks that contraindicate the use of a capsule gastric endoscopy system, or those deemed unsuitable for participation in this study at the discretion of the investigator.",true,"ALL","18 Years",{"count":20,"type":21},482,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to evaluate the diagnostic accuracy of the AI-integrated Capsule Gastroscopy (ACG) system in simulated home-use conditions for detecting upper gastrointestinal (UGI) abnormalities. It will also compare the diagnostic accuracy and time efficiency of AI-assisted interpretation versus manual reading of ACG data. The main questions it aims to answer are:\n\nWhat is the diagnostic accuracy of the ACG system, using conventional esophagogastroduodenoscopy (EGD) as a standard of reference?\n\nDoes AI-assisted ACG reading improve diagnostic accuracy or reduce reading time compared to manual ACG video reading?\n\nResearchers will compare ACG results to conventional EGD findings (standard of reference) to determine if ACG can serve as a reliable method for UGI disease detection in home scenarios.\n\nParticipants will:\n\nUndergo an ACG examination in a simulated home environment. Complete an EGD procedure within 24 hours post-ACG ingestion.",[27,28,29,30,31,32],"Gastric Lesion","Gastritis","Upper Gastrointestinal Bleeding (UGIB)","Gastric Dysplasia","Gastric Ulcer","Gastric Neoplasms",[34,35,36,37,38],"upper gastrointestinal diseases","Capsule Endoscopy","Prospective Study","Diagnostic accuracy","Upper Gastrointestinal abnormalities","RECRUITING","2025-07-03",{"date":42,"type":43},"2025-07-09","ACTUAL",{"date":45,"type":43},"2025-03-03",{"date":47,"type":21},"2026-12-31",{"name":49,"class":50},"Nanfang Hospital, Southern Medical University","OTHER",12,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":22,"phases":61,"briefSummary":62,"conditions":63,"keywords":66,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":78},"100504902","circulating-biomarker-signatures-for-the-detection-of-gastric-preneoplasia-and-cancer-100504902","NCT05854368","Circulating Biomarker Signatures for the Detection of Gastric Preneoplasia and Cancer","PREGASIGN#1","Inclusion Criteria:\n\nCommon\n\n* 18 years old or highter\n* written informed consent prior to any study procedure\n* Affiliated to a social insurance system\n\nSpecific to patients with gastric lesions\n\n* Untreated glandular atrophy (with or without intestinal metaplasia and\u002For dysplasia) and histologically diagnosed as of 2014\n* Treatment naïve Gastric cancer (distal or proximal adenocarcinoma)\n\nExclusion Criteria:\n\nCommon\n\n* Autoimmune disease or disease that impacts the immune system (e.g: HIV)\n* Chronic inflammatory disease\n* Known evolutive cancer (excluding gastric cancer)\n* Treated in the last 3 months or currently treated with therapy that interferes with the immune system (e.g. immunosuppressive therapy)\n* Current treatment with long-term corticosteroid therapy\n* Current treatment with long-term nonsteroidal anti-inflammatory drugs\n* Pregnant woman or breastfeeding\n* Patient or healthy volunteer under legal protection (e.g. guardianship)\n* Patient or healthy volunteer currently participating to a clinical trial evaluating either an experimental medical product or a medical device\n* Patient or healthy volunteer currently in custody\n\nSpecific to Healthy Volunteer\n\n* Known history of Helicobacter pylori infection\n* Known history of gastric lesions (i.e. chronic gastritis, gastric atrophy, intestinal metaplasia, dysplasia and cancer)",{"count":60,"type":21},2500,[24],"The goal of this study is to characterize and validate a signature of circulating biomarkers in plasma, associated with the presence of gastric preneoplasia in patients with preexisting gastric lesion compared with a control group.\n\nFor this purpose:\n\n* Patients with pre-existing gastric lesions will be invited to participate to this study. If they are willing to participate an additional blood sample (9 mL) will be collected at the time of the blood collection performed during their routine care\n* Healthy subjects will be invited to participate to constitute the control group. If they are willing to participate a blood sample (9 ml) will be drawn specifically for this study",[27,64,65],"Gastric Precancerous Condition","Gastric Cancer",[67],"Gastric Cancer, biomarkers,","2025-05-13",{"date":70,"type":43},"2025-05-16",{"date":72,"type":43},"2023-07-03",{"date":74,"type":21},"2025-12",{"name":76,"class":77},"Institut Pasteur","INDUSTRY",8,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":17,"minAge":86,"maxAge":87,"enrollmentInfo":88,"targetDuration":4,"studyType":22,"phases":90,"briefSummary":91,"conditions":92,"keywords":95,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":109},"100476453","lactobacillus-reuteri-strain-combination-in-children-treated-with-ppi-100476453","NCT05484128","Lactobacillus Reuteri Strain Combination in Children Treated With PPI","Lactobacillus Reuteri Strain Combination (Strains DSM 17938 and ATCC PTA 6475) in Children Treated With Proton Pump Inhibitors","Inclusion Criteria:\n\n* Age: children between 1 month and 14 years of age;\n\n  o We start with children older than 4 years of age.\n* Necessity of therapy with Proton Pump Inhibitors for Gastroesophageal reflux disease and\u002For Functional Dyspepsia;\n* Informed consent obtained.\n\nExclusion Criteria:\n\n* Neurological pathologies (PCI and Spastic tetra-paresis);\n* Nasogastric feeding;\n* Known immunodeficiency;\n* Previous therapy with gastric acid inhibitors;\n* HP infection;\n* Assumption of prebiotics, other probiotics or symbiotics in the previous month;\n* Malnutrition or severe dystrophy;\n* Cystic Fibrosis.","12 Months","14 Years",{"count":89,"type":21},172,[24],"Probiotics might be of help in preventing dysbiosis and emergence of SIBO. Gastrus consisted of a mixture of two human strains of L. Reuteri DSM 17938 and ATCC PTA 6475; the first have extensive data supporting its use in gastric infections (18) however, it lacks the anti-inflammatory properties that have been provided by L. Reuteri DSM ATCC PTA 6475 that has excellent acid resistance and has strong anti-inflammatory properties (19); for these reasons, Gastrus is the best candidate for this indication.",[27,93,94],"Proton Pump Inhibitor Adverse Reaction","Probiotic",[96,97,98,99],"Reuteri","Proton Pump Inhibitor","gastrus","infections","2024-12-03",{"date":102,"type":43},"2024-12-05",{"date":104,"type":43},"2020-03-04",{"date":106,"type":21},"2025-12-31",{"name":108,"class":50},"University of Bari",1,{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":4,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":117,"targetDuration":119,"studyType":120,"phases":4,"briefSummary":121,"conditions":122,"keywords":123,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":135,"locationsCount":137},"100481623","the-epigastricedgar-project-new-strategies-for-the-early-detection-and-prevention-of-gastric-cancer-100481623","NCT05551416","The EpiGASTRIC\u002FEDGAR Project: New Strategies for the Early Detection and Prevention of Gastric Cancer","Research and Development of New Strategies for the Early Detection and Prevention of Gastric Cancer in the Spanish Population: EpiGASTRIC\u002FEDGAR Project.","Inclusion Criteria:\n\n* Adults over 18 years-old.\n* EDGAR 1 cohort: symptomatic patients undergoing a diagnostic gastroscopy for a prevalence study of PGLs.\n* EDGAR 2 cohort: PGLs and early GC with indication for endoscopic resection.\n* EPIGASTRIC cohort: patients diagnosed with GC.\n* CONTROL cohort: patients without gastric pathology or a familial history of GC, obtained from the EDGAR 1.\n\nExclusion Criteria:\n\n* Refusal of the patient to participate in the study.\n* Medical, psychological or legal inability of the patient to enter the study.\n* EDGAR1: Previous diagnosis of PGLs, previous gastric surgery, contraindication for gastroscopy or taking biopsies.\n* EDGAR 2: Contraindication for resection\u002Fbiopsy.\n* EPIGASTRIC: gastric neoplasm other than adenocarcinoma.",{"count":118,"type":21},1200,"10 Years","OBSERVATIONAL","This study is a multicenter, prospective cohort study, which are planned to enroll at least 600 patients who diagnosed the primary gastric cancer (GC); around 50 patients with premalignant gastric lesions (PGLs) and early gastric neoplasias (EGC) treated by endoscopy resection; and no less than 600 healthy normal cohort participants, for more than 18 months in the Spanish population. All participants who enrolled in this registry will be questioned by the life habits survey; and clinical data and biological samples of these participants were analyzed in order to look for new diagnostic tools.\n\nThe aim of this study is to evaluate clinical, endoscopic and molecular approaches to identify individuals with high-risk of GC. Thus, it would be allow the adoption of preventive measures to reduce mortality through early detection and\u002For the reduction of its incidence.",[32,65,27],[65,124,125,126,127,128],"Premalignant gastric lesions","Biomarkers","Prevalence","Endoscopy","Multiomics","2023-10-23",{"date":131,"type":43},"2023-10-24",{"date":133,"type":43},"2021-09-09",{"date":47,"type":21},{"name":136,"class":50},"EDUARDO ALBENIZ",15]